Ranbaxy Agrees To Pay $500 Million To Resolve Manufacturing Violations At Indian Sites
This article was originally published in PharmAsia News
In the final stage of a drawn-out saga, Ranbaxy will pay $500 million to U.S. federal agencies to settle civil and criminal proceedings related to manufacture and supply of adulterated drugs from two Indian sites.
You may also be interested in...
Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.